Purine Nucleoside Phosphorylase Inhibition as a Novel Therapeutic Approach for B-Cell Lymphoid Malignancies

References 

1. Markert ML. Purine nucleoside phosphorylase deficiency. Immunodef Rev. 1991;3:45–81
2. Montgomery JA. Inhibitors of purine nucleoside phosphorylase. Exp Opin Invest Drugs. 1994;3:1303–1313
3. Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—A novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1:1199–1210
   • MEDLINE
   • CrossRef
4. Bantia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Discov Devel. 2004;7:243–247
   • MEDLINE
5. Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81:597–601
   • MEDLINE
6. Balakrishnan K, Nimmanapalli R, Ravandi F, et al. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006;108:2392–2398
   • MEDLINE
   • CrossRef
7. Furman RR, Gandhi VV, Bennett JC, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood. 2004;104(suppl 1):750a;(abstr 2743)
8. Ritchie E, Gore L, Roboz G, et al. Phase II study of forodesine, a PNP inhibitor, in patients with relapsed or refractory B-lineage acute lymphoblastic leukemia. 2006;Poster presented at the American Society of Hematology 48th Annual Meeting, Orlando, FL, December